BNGO Quote, Financials, Valuation and Earnings

Azenta has a net margin of -48.04% compared to Bionano Genomics's net margin of -28.21%. Bionano Genomics's return on equity of -141.6% beat Azenta's return on equity of -3.48%.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 115.69%. On the other hand Azenta has an analysts' consensus of $33.75 which suggests that it could grow by 5.21%. Given that Bionano Genomics has higher upside potential than Azenta, analysts believe Bionano Genomics is more attractive than Azenta.

Bionano Genomics has a beta of 2.207, which suggesting that the stock is 120.694% more volatile than S&P 500. In comparison Azenta has a beta of 1.637, suggesting its more volatile than the S&P 500 by 63.674%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Azenta offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Azenta pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.5M, which are smaller than Azenta quarterly revenues of $143.4M. Bionano Genomics's net income of -$3.1M is higher than Azenta's net income of -$40.5M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Azenta's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.17x versus 2.43x for Azenta. Usually stocks with elevated PS ratios are considered overvalued.

Bruker has a net margin of -48.04% compared to Bionano Genomics's net margin of 2.17%. Bionano Genomics's return on equity of -141.6% beat Bruker's return on equity of 4.53%.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 115.69%. On the other hand Bruker has an analysts' consensus of $54.11 which suggests that it could grow by 30.26%. Given that Bionano Genomics has higher upside potential than Bruker, analysts believe Bionano Genomics is more attractive than Bruker.

Bionano Genomics has a beta of 2.207, which suggesting that the stock is 120.694% more volatile than S&P 500. In comparison Bruker has a beta of 1.181, suggesting its more volatile than the S&P 500 by 18.13%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.48% to investors and pays a quarterly dividend of $0.05 per share. Bionano Genomics pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Bionano Genomics quarterly revenues are $6.5M, which are smaller than Bruker quarterly revenues of $801.4M. Bionano Genomics's net income of -$3.1M is lower than Bruker's net income of $17.4M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Bruker's PE ratio is 79.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.17x versus 1.82x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.

Harvard Bioscience has a net margin of -48.04% compared to Bionano Genomics's net margin of -231.19%. Bionano Genomics's return on equity of -141.6% beat Harvard Bioscience's return on equity of -103.83%.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 115.69%. On the other hand Harvard Bioscience has an analysts' consensus of $3.00 which suggests that it could grow by 640.74%. Given that Harvard Bioscience has higher upside potential than Bionano Genomics, analysts believe Harvard Bioscience is more attractive than Bionano Genomics.

Bionano Genomics has a beta of 2.207, which suggesting that the stock is 120.694% more volatile than S&P 500. In comparison Harvard Bioscience has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.373%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Harvard Bioscience offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Harvard Bioscience pays out -- of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.5M, which are smaller than Harvard Bioscience quarterly revenues of $21.8M. Bionano Genomics's net income of -$3.1M is higher than Harvard Bioscience's net income of -$50.3M. Notably, Bionano Genomics's price-to-earnings ratio is -- while Harvard Bioscience's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.17x versus 0.19x for Harvard Bioscience. Usually stocks with elevated PS ratios are considered overvalued.

Kestra Medical Technologies has a net margin of -48.04% compared to Bionano Genomics's net margin of --. Bionano Genomics's return on equity of -141.6% beat Kestra Medical Technologies's return on equity of --.

Bionano Genomics has a consensus price target of $7.33, signalling upside risk potential of 115.69%. On the other hand Kestra Medical Technologies has an analysts' consensus of $26.83 which suggests that it could grow by 74.81%. Given that Bionano Genomics has higher upside potential than Kestra Medical Technologies, analysts believe Bionano Genomics is more attractive than Kestra Medical Technologies.

Bionano Genomics has a beta of 2.207, which suggesting that the stock is 120.694% more volatile than S&P 500. In comparison Kestra Medical Technologies has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Bionano Genomics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Kestra Medical Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bionano Genomics pays -- of its earnings as a dividend. Kestra Medical Technologies pays out -1.99% of its earnings as a dividend.

Bionano Genomics quarterly revenues are $6.5M, which are larger than Kestra Medical Technologies quarterly revenues of --. Bionano Genomics's net income of -$3.1M is higher than Kestra Medical Technologies's net income of --. Notably, Bionano Genomics's price-to-earnings ratio is -- while Kestra Medical Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bionano Genomics is 0.17x versus 15.34x for Kestra Medical Technologies. Usually stocks with elevated PS ratios are considered overvalued.